Pharmafile Logo

Takeda Pharmaceutical Company

European Commission Approves ADCETRIS (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD  

· Approval Based on Updated Positive Overall Survival Results from the phase 3 ECHELON-1 Study for Stage III & IV Hodgkin Lymphoma  · First Significant Improvement in Overall Survival in Two Decades in Stage III & IV Hodgkin Lymphoma  ·  Approval Expands on Six Current Indications for ADCETRIS in the EU  October 18, 2023 -- Osaka, Japan...

NINLARO (ixazomib) receives conditional approval from the European Commission to treat relapsed or refractory multiple myeloma

Takeda UK, High Wycombe, UK, November 29, 2016 - Takeda Pharmaceutical Company Limited today announced that the European Commission has granted conditional marketing authorisation for NINLARO (ixazomib) capsules, indicated in combination with lenalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy. The decision to approve ixazomib as...
https://betterhealth.takeda.com/
61 Aldwych, London, WC2B 4AE, UK

020 3116 8000